Immunome, Inc.IMNMNASDAQ
LOADING
|||

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
9 analysts·Limited coverage
100%
Rating Distribution
Strong Buy
00%
Buy
9100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 32% higher.

Bear Case
$26.00
-1%
Consensus
$34.50
+32%
Bull Case
$40.00
+53%
Price Range9 analysts
Low
Consensus
High
$26.00
$40.00
Current Target
Current Price
$26.14
Upside to Target
$8.36

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 16, 2025Lake Street
Immunome price target raised to $32 from $22 at Lake Street
Target:$32.00
+36.8%from $23.39
Dec 16, 2025Evercore ISI
Immunome price target raised to $40 from $18 at Evercore ISI
Target:$40.00
+71.3%from $23.35
Dec 15, 2025Leerink Partners
Immunome price target raised to $40 from $38 at Leerink
Target:$40.00
+76.6%from $22.65
Dec 1, 2025Truist Financial
Immunome initiated with a Buy at Truist
Target:$36.00
+95.4%from $18.42
Nov 17, 2025Stephens
Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login
Target:$33.00
+92.5%from $17.14
Sep 5, 2025Craig-Hallum
Immunome initiated with a Buy at Craig-Hallum
Target:$26.00
+147.1%from $10.52
Aug 22, 2025Evercore ISI
Immunome initiated with an Outperform at Evercore ISI
Target:$18.00
+74.8%from $10.30
Aug 13, 2024Piper Sandler
Immunome price target lowered to $23 from $27 at Piper Sandler
Target:$23.00
+82.0%from $12.64
Apr 15, 2024Guggenheim
Immunome initiated with a Buy at Guggenheim
Target:$35.00
+70.1%from $20.58
Apr 1, 2024Wedbush
Immunome price target raised to $33 from $27 at Wedbush
Target:$33.00
+33.7%from $24.68